Xanthine Oxidase Inhibition in Renal Transplant Recipients (XART)

Roberto S Kalil

Status and phase: Terminated; Phase 4

Conditions: Complications of Renal Transplant

Treatments: Other: Placebo; Drug: allopurinol or placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT01332799

201010787

Details and patient eligibility

About

Cardiovascular disease is the leading cause of mortality in kidney transplantation. The enzyme xanthine oxidase may play an important role in the cardiovascular disease of kidney transplant recipients. Inhibiting this enzyme with allopurinol may improve vascular health and protects against cardiovascular complications.

Full description

This is a prospective, double-blind, placebo controlled, clinical trial examining vascular effects of allopurinol in patients who received a kidney transplant that are maintaining stable renal function for at least 1 year. End-points include pulse-wave velocity, systemic blood pressure and kidney function among others.

Enrollment: 20 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age 18 years or older
• both genders
• recipients of living donor or deceased-donor kidney transplant with stable renal function

Exclusion criteria

• history of gout
• allergy to allopurinol
• use of azathioprine

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

20 participants in 2 patient groups, including a placebo group

Allopurinol

Active Comparator group

Treatment:

Drug: allopurinol or placebo

Placebo (sugar pill)

Placebo Comparator group

Treatment:

Other: Placebo